New IPC Councilor

New Psoriasis Expert Joins the Group of Respected IPC Councilors

IPC is pleased to introduce and welcome our newest councilor in 2022, Claus Johansen. Dr. Johansen was confirmed by the IPC Board of Directors during their Board meeting in June and adds to our diverse and broad experience of psoriasis experts that are passionate about working to improve care for psoriasis patients around the world. IPC Councilors serve in an advisory capacity and lend their global expertise on psoriasis research, treatment, and education to support all IPC programs, events, and initiatives. They are selected based on their overall reputation in the dermatology community, experience in clinical or investigative research in psoriasis, level of clinical expertise in patient care, and demonstrated professional interest in psoriasis. Learn more about IPC Councilors and read their full biographies.

Meet our newest councilor

Claus Johansen, MSc, PhD, DMSc
Aarhus University Hospital
Aarhus, Denmark

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis

Commentary: Trajectories and Prognosis after Discontinuation of Biologics due to Remission in Psoriasis – A Nationwide Cohort Study

IFPA and IPC Partnership One Year Later — Joining the Clinical and Patient Perspectives

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

New IPC Councilor

New Psoriasis Expert Joins the Group of Respected IPC Councilors

Meet our newest councilor

Leave a Reply Cancel reply

Categories

Recent Posts

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis

Commentary: Trajectories and Prognosis after Discontinuation of Biologics due to Remission in Psoriasis – A Nationwide Cohort Study

IFPA and IPC Partnership One Year Later — Joining the Clinical and Patient Perspectives

Also Read

IFPA and IPC Partnership One Year Later — Joining the Clinical and Patient Perspectives

Meet Our Newest Councilors

IPC and IFPA Joint Statement on Diversity and Inclusion

Subscribe to the IPC Newsletter

Quick Links

Follow us